Halozyme Therapeutics Inc
Open
SectorGezondheidszorg
81.25 -0.76
Overzicht
Wijziging aandelenprijs
24u
Min
81.54
Max
83.4
Inkomsten | 292M 150M |
|---|---|
Verkoop | -75M 377M |
K/W Sectorgemiddelde | 27.337 62.58 |
EPS | 1.221 |
Winstmarge | 39.832 |
Werknemers | 423 |
EBITDA | -62M 220M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | -1.14% downside |
Marktkapitalisatie | 1.5B 9.1B |
|---|---|
Vorige openingsprijs | 82.01 |
Vorige sluitingsprijs | 81.25 |
Halozyme Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Halozyme Therapeutics Inc Prognose
Koersdoel
By TipRanks
-1.14% neerwaarts potentieel
12 Maanden Prognose
Gemiddelde 81 USD -1.14%
Hoogste 96 USD
Laagste 57 USD
Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.
Financieel
$
Over Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
